Aemetis Q2 EPS Reduced by Ascendiant Capital Markets

Aemetis, Inc (NASDAQ:AMTX) – Investment analysts at Ascendiant Capital Markets lowered their Q2 2026 earnings per share estimates for shares of Aemetis in a research report issued on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo now expects that the specialty chemicals company will post earnings per share of ($0.21) for the quarter, down from their previous estimate of ($0.20). Ascendiant Capital Markets currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Aemetis’ current full-year earnings is ($2.07) per share. Ascendiant Capital Markets also issued estimates for Aemetis’ Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.86) EPS.

Several other analysts also recently weighed in on the stock. Loop Capital set a $1.75 price objective on shares of Aemetis in a research report on Thursday, March 12th. Wall Street Zen upgraded shares of Aemetis from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aemetis in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.58.

Aemetis Stock Performance

Shares of AMTX opened at $2.33 on Wednesday. The firm has a fifty day moving average of $2.12 and a 200-day moving average of $1.97. The company has a market cap of $158.79 million, a price-to-earnings ratio of -1.75 and a beta of 1.48. Aemetis has a 1 year low of $1.22 and a 1 year high of $3.66.

Aemetis (NASDAQ:AMTX) last issued its quarterly earnings data on Thursday, March 12th. The specialty chemicals company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $43.31 million for the quarter, compared to the consensus estimate of $72.07 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its position in Aemetis by 71.9% in the first quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock worth $380,000 after purchasing an additional 91,367 shares during the period. Creative Planning acquired a new position in shares of Aemetis during the 2nd quarter valued at $30,000. Russell Investments Group Ltd. increased its position in shares of Aemetis by 412.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company’s stock valued at $200,000 after purchasing an additional 65,010 shares during the period. Jump Financial LLC bought a new stake in shares of Aemetis in the 2nd quarter worth $64,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Aemetis in the second quarter valued at $246,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.